- <90> Fetal Bovine Serum Quality Attributes and Functionality (posted 05–Feb–2021)
- <661.1> Plastic Materials of Construction Notice of Intent to Revise (posted 18–Dec–2020)
- Albuterol Inhalation Solution Notice of Intent to Revise (posted 16–Apr–2021)
- Amantadine Hydrochloride Notice of Intent to Revise (posted 27–May–2020)
- Aminocaproic Acid Oral Solution Notice of Intent to Revise (posted 31–Jul–2020)
- Aprepitant Capsules, Galantamine Tablets, Praziquantel Tablets, and <1092> The Dissolution Procedure: Development and Validation Notice of Intent to Revise (posted 28–Aug–2020)
- Benztropine Mesylate Notice of Intent to Revise (posted 28–Dec–2020)
- Bupropion Hydrochloride Notice of Intent to Revise (posted 19–Feb–2021)
- Castor Oil Notice of Intent to Revise (posted 31–Jul–2020)
- Codeine Phosphate Notice of Intent to Revise (posted 26–Mar–2021)
- Deferred Proposal: General Notices and Requirements, 5.60.40 Impurities that are Unusually Toxic and/or Mutagenic (posted 30–Sep–2020)
- Diphenhydramine Hydrochloride Oral Powder Notice of Intent to Revise (posted 25–Sep–2020)
- Clonidine Transdermal System Notice of Intent to Revise (posted 27–Mar–2020)
- Gemfibrozil Tablets Notice of Intent to Revise (posted 28–Aug–2020)
- Lactobacillus Rhamnosus Notice of Intent to Revise (posted 20–Nov–2020)
- Lauroyl Polyoxyglycerides Notice of Intent to Revise (posted 19–Feb–2021)
- Pyrazinamide Notice of Intent to Revise (posted 19–Feb–2021)
- Sucrose Notice of Intent to Revise (posted 26–Feb–2021; updated 02–Apr–2021)
- Talc Notice of Intent to Revise (updated 18–Dec–2020)
- Tetracycline, Tetracycline Hydrochloride and Tetracycline Hydrochloride Capsules Notice of Intent to Revise (posted 18–Dec–2020)
